Immutep マネジメント

マネジメント基準チェック /34

Immutepの CEO はMarc Voigtで、 Nov2012年に任命され、の在任期間は 10.33年です。の年間総報酬はA$ 1.06Mで、 44.8%給与と55.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.78%を直接所有しており、その価値はA$ 3.04M 。経営陣と取締役会の平均在任期間はそれぞれ6.9年と2.5年です。

主要情報

Marc Voigt

最高経営責任者

AU$1.1m

報酬総額

CEO給与比率	44.8%
CEO在任期間	12yrs
CEOの所有権	0.8%
経営陣の平均在職期間	6.9yrs
取締役会の平均在任期間	2.5yrs

経営陣の近況

Recent updates

Is Immutep (ASX:IMM) Weighed On By Its Debt Load?

May 19

CEO報酬分析

Immutep の収益と比較して、Marc Voigt の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	AU$1m	AU$477k	-AU$43m
Mar 31 2024	n/a	n/a	-AU$42m
Dec 31 2023	n/a	n/a	-AU$41m
Sep 30 2023	n/a	n/a	-AU$40m
Jun 30 2023	AU$1m	AU$440k	-AU$40m
Mar 31 2023	n/a	n/a	-AU$38m
Dec 31 2022	n/a	n/a	-AU$37m
Sep 30 2022	n/a	n/a	-AU$34m
Jun 30 2022	AU$943k	AU$428k	-AU$32m
Mar 31 2022	n/a	n/a	-AU$29m
Dec 31 2021	n/a	n/a	-AU$26m
Sep 30 2021	n/a	n/a	-AU$28m
Jun 30 2021	AU$995k	AU$409k	-AU$30m
Mar 31 2021	n/a	n/a	-AU$29m
Dec 31 2020	n/a	n/a	-AU$27m
Sep 30 2020	n/a	n/a	-AU$20m
Jun 30 2020	AU$926k	AU$411k	-AU$13m
Mar 31 2020	n/a	n/a	-AU$15m
Dec 31 2019	n/a	n/a	-AU$16m
Sep 30 2019	n/a	n/a	-AU$17m
Jun 30 2019	AU$837k	AU$399k	-AU$18m
Mar 31 2019	n/a	n/a	-AU$18m
Dec 31 2018	n/a	n/a	-AU$17m
Sep 30 2018	n/a	n/a	-AU$15m
Jun 30 2018	AU$1m	AU$401k	-AU$13m

報酬と市場: Marcの総報酬 ($USD 706.01K ) は、 Australian市場 ($USD 665.93K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Marcの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Marc Voigt (51 yo)

12yrs

在職期間

AU$1,064,669

報酬

Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been an Executive Director of Immutep Limited since July 9, 2014. He se...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Marc Voigt	CEO, MD	12yrs	AU$1.06m	0.78% A$ 3.0m
Deanne Miller	COO, General Counsel & Joint Company Secretary	12.1yrs	AU$565.23k	0.18% A$ 720.2k
Frederic Triebel	Chief Scientific Officer & Executive Director	9.9yrs	AU$864.44k	0.61% A$ 2.4m
Florian Vogl	Chief Medical Officer	1.5yrs	AU$955.82k	データなし
Christian Mueller	Senior Vice President of Regulatory & Strategy	1.1yrs	データなし	データなし
Indira Naidu	Joint Company Secretary	3.8yrs	データなし	データなし

6.9yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: IMMの経営陣は経験豊富で経験豊富です（平均在職期間は6.9年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Marc Voigt	CEO, MD	10.3yrs	AU$1.06m	0.78% A$ 3.0m
Frederic Triebel	Chief Scientific Officer & Executive Director	2.2yrs	AU$864.44k	0.61% A$ 2.4m
Russell Howard	Independent Non-Executive Chairman	11.5yrs	AU$163.52k	0.077% A$ 300.6k
Pete Meyers	Independent Non-Executive Deputy Chairman	10.8yrs	AU$138.71k	0.25% A$ 989.1k
Martine Piccart	Chairman of Clinical Advisory Board	7.4yrs	データなし	データなし
Scott Antonia	Member of Clinical Advisory Board	2.5yrs	データなし	データなし
Leisha Emens	Member of Clinical Advisory Board	2.5yrs	データなし	データなし
Elisabeth Boyce	Non-Executive Director	1.6yrs	AU$144.76k	データなし
Salah-Eddin Al-Batran	Member of Clinical Advisory Board	7.4yrs	データなし	データなし
Martin Forster	Member of Clinical Advisory Board	2.5yrs	データなし	データなし
Hans Wildiers	Member of Clinical Advisory Board	2.5yrs	データなし	データなし

2.5yrs

平均在職期間

61.5yo

平均年齢

経験豊富なボード: IMMの取締役会は経験豊富ではない ( 2.5年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Immutep マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Limited, Annual General Meeting, Oct 24, 2023

Less than half of directors are independent

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Appoints Frederic Triebel as Executive Director

Recent updates

Immutep Limited, Annual General Meeting, Nov 22, 2024

Immutep Limited Announces Resignation of Anne Anderson as Independent Non-Executive Director

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

Immutep Limited Announces New Data from Eftisarc-Neo Phase II Evaluating Novel Triple Combination Including Immutep's Efti in Soft Tissue Sarcoma

Immutep Limited Announces Positive Efficacy and Safety Results from the TACTI-003 Phase IIb Trial Evaluating Eftilagimod Alpha

Consensus revenue estimates increase by 64%

Consensus revenue estimates increase by 16%

Full year 2024 earnings: EPS and revenues exceed analyst expectations

No longer forecast to breakeven

Immutep Limited Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress

Immutep Announces First Participant Dosed in Phase I Study of Imp761, A First in Class Agonist Lag-3 Antibody

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

Immutep Limited Receives Regulatory Clearance for Phase I Study of First-In-Class Lag-3 Agonist Antibody Designed to Treat Autoimmune Diseases

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative Pd-L1 Expression

New minor risk - Shareholder dilution

No longer forecast to breakeven

Immutep Limited Announces Clinical Collaboration with Msd to Evaluate Efti in Combination with Keytruda®? (Pembrolizumab) in Pivotal Phase Iii Trial

Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024

Immutep Limited Reports Positive Initial Clinical Data Reported from Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma

Price target increased by 8.1% to AU$0.97

Immutep Limited Announces Positive Preliminary Topline Results from TACTI-003 Cohort B

New minor risk - Profitability

Immutep Limited Appoints Leading Research Institute to Conduct First-In-Human Phase I Study of IMP761

Immutep Limited Receives Positive Feedback from the Spanish Medicines Agency for Upcoming Tacti-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Price target decreased by 29% to AU$0.90

Immutep Limited Announces First Clinical Data from 90Mg Dosing of Efti

Immutep Limited Announces First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO in Metastatic Urothelial Cancer

Immutep Limited Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 54%

Immutep Limited Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA(R) in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Immutep Announces New Biomarker Data from Tacti-002 Phase II in First Line Non-Small Cell Lung Cancer

Immutep Limited Reports Promising Clinical Data from Insight-003 Trial at ESMO Congress 2023

Consensus EPS estimates upgraded to AU$0.024 loss

Immutep Limited Announces Excellent New Clinical Data from the TACTI-002 / KEYNOTE-798 Phase II Trial Evaluating Eftilagimod Alpha

Immutep Limited Announces Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

Consensus EPS estimates fall by 58%

Immutep Limited, Annual General Meeting, Oct 24, 2023

Consensus revenue estimates decrease by 77%, EPS upgraded

Full year 2023 earnings: EPS and revenues miss analyst expectations

Immutep Limited Receives Positive Scientific Advice from Committee for Medicinal Products for Human Use of European Medicines Agency for Continued Development of Eftilagimod Alpha

Immutep Limited Announces First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma

Forecast to breakeven in 2026

Consensus EPS estimates upgraded to AU$0.052 loss

Immutep Limited Doses First Patient in AIPAC-003 Phase II/III Trial for Metastatic Breast Cancer

Immutep Limited Announces Efti in Combination with Pembrolizumab Achieves Excellent Initial Overall Survival Benefit in 1st Line Non-Small Cell Lung Cancer

Consensus EPS estimates fall by 23%

Immutep Limited Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alpha in Non-Small Cell Lung Cancer

Consensus revenue estimates increase by 19%

Price target increased by 15% to AU$1.33

No longer forecast to breakeven

Consensus revenue estimates increase by 20%

First half 2023 earnings released: AU$0.024 loss per share (vs AU$0.019 loss in 1H 2022)

Immutep Reaches Enrolment Target for INSIGHT-003 Trial in 1st Line NSCLC

Immutep Limited Announces Update on INSIGHT-003 Trial in NSCLC

Consensus forecasts updated

Immutep Limited Enrolls and Randomised over 50% of the Planned 154 Patients in the Tacti-003 Phase IIB Trial

Immutep Limited Announces the Results of Positive Follow-Up Type C Meeting with the US Food and Drug Administration

Immutep Limited Announces the Successful Scale-Up of the Manufacturing of its Lead Product Candidate Eftilagimod Alpha

Immutep Limited Announces GMP Manufacturing Process Developed for IMP761, a First-in-Class LAG-3 Agonist for Autoimmune Disease

Less than half of directors are independent

Consensus forecasts updated

Immutep Limited Announces Compelling Clinical Results from Phase II Trial Utilizing its First-in-Class Soluble LAG-3 Protein, Eftilagimod Alpha, in 1st Line NSCLC at SITC 2022 Annual Meeting

Immutep Limited Announces Independent Data Monitoring Committee Positive Recommendation to Continue TACTI-003 Trial as Planned

Immutep Limited Announces the United States Food and Drug Administration (Fda) Has Granted Fast Track Designation to Eftilagimod Alpha

Consensus forecasts updated

Immutep Limited, Annual General Meeting, Nov 23, 2022

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Clinical Development Update for its LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha

Immutep Appoints Frederic Triebel as Executive Director

マネジメント基準チェック /34